10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.

Employees

1,259

Sector

Medical Equipment, Supplies & Distribution

Calendar

29/10/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
09/09/24	22.04 $	+2.34%	362,143
06/09/24	21.54 $	-6.91%	1,862,613
05/09/24	23.14 $	+1.18%	840,573
04/09/24	22.87 $	-0.69%	817,314
03/09/24	23.03 $	-1.37%	1,202,640

Delayed Quote Nasdaq, September 09, 2024 at 06:17 pm

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

21.54USD

Average target price

27.29USD

Spread / Average Target

+26.67%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Real-time Estimate Cboe BZX Other stock markets 18:32:09 09/09/2024 BST			5-day change	1st Jan Change
22.02 ^USD	+2.23%		-4.21%	-60.58%

09-04	Transcript : 10x Genomics, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 10:45 AM
09-03	10x Genomics, Inc. Announces Launch of Chromium Xo, A New Addition to Its Fleet of Chromium Single Cell Instruments	CI

Capitalization	2.6B 198B	P/E ratio 2024 *	-16.3x	P/E ratio 2025 *	-24.3x
Enterprise value	2.24B 171B	EV / Sales 2024 *	3.46x	EV / Sales 2025 *	3.04x
Free-Float	85.82%	Yield 2024 *	-	Yield 2025 *	-

Transcript : 10x Genomics, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 10:45 AM	09-04
10x Genomics, Inc. Announces Launch of Chromium Xo, A New Addition to Its Fleet of Chromium Single Cell Instruments	09-03	CI
Leerink Partners Initiates 10x Genomics at Outperform	09-03	MT
UBS Adjusts Price Target on 10x Genomics to $25 From $30, Maintains Neutral Rating	08-13	MT
Tech, Yen, and Jobs: Wall Street's triple play	08-09
Analyst recommendations: Epam Systems, Five9, T-Mobile, Lyft, Under Armour...	08-09
Earnings Flash (TXG) 10X GENOMICS Posts Q2 Revenue $153.1M	08-08	MT
Earnings Flash (TXG) 10X GENOMICS Posts Q2 Loss $-0.32	08-08	MT
Transcript : 10x Genomics, Inc., Q2 2024 Earnings Call, Aug 08, 2024	08-08
10x Genomics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	08-08	CI
10X Genomics, Inc. Appoints Mennah Moustafahas as Chief Commercial Officer	08-08	CI
10X Genomics, Inc. Announces CFO Changes	08-08	CI
10X Genomics, Inc. Revises Earnings Guidance for Full Year 2024	08-08	CI

Leerink Partners Initiates 10x Genomics at Outperform	09-03	MT
UBS Adjusts Price Target on 10x Genomics to $25 From $30, Maintains Neutral Rating	08-13	MT
Analyst recommendations: Epam Systems, Five9, T-Mobile, Lyft, Under Armour...	08-09
Canaccord Genuity Adjusts Price Target on 10x Genomics to $32 From $50, Maintains Buy Rating	07-23	MT
Analyst recommendations: CrowdStrike, Johnson & Johnson, Netflix, Nvidia, Snap...	07-23

10x Genomics, Inc. Share Price

Equities

TXG

US88025U1097

Medical Equipment, Supplies & Distribution

Valuation: 10x Genomics, Inc.

Chart: 10x Genomics, Inc.

Latest news: 10x Genomics, Inc.

Last Transcript: 10x Genomics, Inc.

Analysts' recommendations: 10x Genomics, Inc.

Press Releases: 10x Genomics, Inc.

News in other languages: 10x Genomics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: 10x Genomics, Inc.

Diagnostic & Testing Substances

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly earnings, Rate of surprise

10x Genomics Unveils Chromium Xo: A Low-Cost Instrument to Expand Access to High-Performance Single Cell Research	09-03	PR
10x Genomics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference	08-22	PR
10x Genomics: Q2 Earnings Snapshot	08-08	AQ
10x Genomics Announces Senior Leadership Changes	08-08	PR
10x Genomics Reports Second Quarter 2024 Financial Results	08-08	PR

RECOMENDACIONES DE LOS ANALISTAS UK/EE.UU.: Epam Systems, Five9, T-Mobile, Lyft, Under Armour...	08-09
RECOMENDACIONES DE LOS ANALISTAS UK/EE.UU. : CrowdStrike, Johnson & Johnson, Netflix, Nvidia, Snap...	07-23
RECOMENDACIONES DE LOS ANALISTAS UK/EE.UU.: Dollar Tree, JPMorgan, Broadcom, Chipotle, Burberry...	07-16
Cathie Wood, nouvelle popstar de l’investissement ?	17/05/21
PUMP / DUMP #10	07/05/21

1 day	+2.30%
1 week	-4.21%
Current month	-5.52%
1 month	+7.98%
3 months	-0.54%
6 months	-45.31%
Current year	-60.58%

Director	Title	Age	Since
Serge Saxonov FOU	Founder	47	01/07/12
Ben Hindson FOU	Founder	49	01/07/12
Adam Taich DFI	Director of Finance/CFO	49	08-11

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
10X GENOMICS, INC.	+2.23%	-4.21%	-54.04%	-88.02%	2.6B
BIOMÉRIEUX	+4.45%	+7.71%	+19.79%	-0.14%	13.84B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	+0.30%	+0.87%	+9.14%	+44.00%	7.45B
LANTHEUS HOLDINGS, INC.	-0.84%	-3.93%	+55.00%	+287.64%	7.08B
DIASORIN S.P.A.	+2.08%	+2.23%	+11.21%	-49.78%	5.99B
VITROLIFE AB	+2.29%	+3.44%	+93.13%	-48.90%	3.34B
AUTOBIO DIAGNOSTICS CO., LTD.	-0.60%	-2.64%	-13.38%	-22.12%	3.26B
ANDON HEALTH CO., LTD.	-1.22%	-0.17%	+15.91%	+477.50%	2.78B
MYRIAD GENETICS, INC.	+0.65%	-1.04%	+66.62%	-20.26%	2.45B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-1.59%	-5.64%	-15.02%	-50.87%	1.4B
Average	+0.79%	-1.42%	+18.84%	+52.91%	5.02B
Weighted average by Cap.	+1.56%	-0.59%	+22.16%	+55.99%

	2024 *	2025 *
Net sales	648M 49.46B	719M 54.87B
Net income	-158M -12.09B	-107M -8.18B
Net Debt	-356M -27.14B	-409M -31.24B